529
Views
36
CrossRef citations to date
0
Altmetric
Research Article

Aβ-induced microglial cell activation is inhibited by baicalin through the JAK2/STAT3 signaling pathway

, , , , , & show all
Pages 609-620 | Received 02 May 2013, Accepted 08 Nov 2013, Published online: 12 Dec 2013
 

Abstract

Baicalin has shown multiple neuroprotective biological activities, including antiapoptotic and anti-inflammatory functions in neurodegeneration diseases. However, whether baicalin can regulate Aβ-induced microglial activation or inhibit inflammatory cytokine secretion has not been confirmed. We demonstrated that baicalin can inhibit beta amyloid peptides (Aβ42)-induced BV2 microglial cell proliferation, reduce the expression of CD11b, decrease chemotactic ability of BV2 cells and significantly inhibit the secretion of IL-6, TNF-α and NO. Moreover, baicalin pretreatment can effectively inhibit Aβ-induced phosphorylation of JAK2 and STAT3. Baicalin can inhibit Aβ-induced microglial cell activation by regulating the JAK2/STAT3 signaling pathway in AD transgenic mice. The modulation of microglial proliferation, activation and secretion by baicalin could be a promising therapeutic option for the treatment of Alzheimer's disease.

This work was supported by the National Natural Science Foundation (Grant no. 81041206) of China and the Traditional Medicine Special Project of PLA of China (Grant no. 10ZYZ244).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.